MAP2K7 and Posterior Leukoencephalopathy Syndrome: Sabile et al. reported on a patient who developed PRES after switching from combination ipilimumab and nivolumab to encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor), which raised the difficulty of determining the precipitating agent [128].